Skip to main content
SpringerLink
Log in

Manage haematological malignancies during pregnancy according to cancer type and gestational stage

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Haematological malignancies that occur during pregnancy are difficult to diagnose and manage. For patients diagnosed during trimester 1, watchful waiting or bridging therapy are options for some types of malignancies, whereas termination should be considered in patients with highly aggressive cancers that require immediate treatment with highly teratogenic agents. The use of chemotherapy is generally considered safe during trimesters 2 and 3. Special considerations should also be given to appropriate supportive care and the timing of delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28(4):683–9.

    Article  PubMed  Google Scholar 

  2. Amit O, Barzilai M, Avivi I. Management of hematologic malignancies: special considerations in pregnant women. Drugs. 2015;75(15):1725–38.

    Article  CAS  PubMed  Google Scholar 

  3. Lavi N, Horowitz NA, Brenner B. An update on the management of hematologic malignancies in pregnancy. Womens Health (Lond Engl). 2014;10(3):255–66.

    Article  CAS  PubMed  Google Scholar 

  4. Koren G, Carey N, Gagnon R, et al. Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can. 2013;35(3):263–80.

    Article  PubMed  Google Scholar 

  5. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.

    Article  PubMed  Google Scholar 

  6. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283–91.

    Article  CAS  PubMed  Google Scholar 

  7. Evens AM, Advani R, Press OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 2013;31(32):4132–9.

    Article  PubMed  Google Scholar 

  8. Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13(3):256–64.

    Article  CAS  PubMed  Google Scholar 

  9. Pereg D, Koren G, Lishner M. The treatment of Hodgkin’s and non-Hodgkin’s lymphoma in pregnancy. Haematologica. 2007;92(9):1230–7.

    Article  PubMed  Google Scholar 

  10. Voulgaris E, Pentheroudakis G, Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg Oncol. 2011;20(4):e175–8.

    Article  CAS  PubMed  Google Scholar 

  11. Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–506.

    Article  CAS  PubMed  Google Scholar 

  12. Sarno MA, Mancari R, Azim HA Jr, et al. Are monoclonal antibodies a safe treatment for cancer during pregnancy? Immunotherapy. 2013;5(7):733–41.

    Article  CAS  PubMed  Google Scholar 

  13. Peres RM, Sanseverino MT, Guimarães JL, et al. Assessment of fetal risk associated with exposure to cancer chemotherapy during pregnancy: a multicenter study. Braz J Med Biol Res. 2001;34(12):1551–9.

    Article  CAS  PubMed  Google Scholar 

  14. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–91.

    Article  CAS  PubMed  Google Scholar 

  15. Breccia M, Cimino G, Alimena G, et al. AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation. Haematologica. 2002;87(2):ELT12.

    PubMed  Google Scholar 

  16. Brojeni PY, Matok I, Bournissen FG, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33(3):265–8.

    Article  Google Scholar 

  17. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505–8.

    Article  CAS  PubMed  Google Scholar 

  18. Matok I, Gorodischer R, Koren G, et al. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med. 2009;360(24):2528–35.

    Article  CAS  PubMed  Google Scholar 

  19. Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13(9):887–96.

    Article  CAS  PubMed  Google Scholar 

  20. Avilés A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2(3):173–7.

    Article  PubMed  Google Scholar 

  21. Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34(4):302–12.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Drugs 2015;75(15):1725–38 [2] by salaried/contracted employee(s) of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Manage haematological malignancies during pregnancy according to cancer type and gestational stage. Drugs Ther Perspect 32, 287–291 (2016). https://doi.org/10.1007/s40267-016-0303-8

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-016-0303-8

    Keywords

    Search

    Navigation